Seattle, WA – According to filings with the U.S. Securities and Exchange Commission, Lumen Bioscience is raising $50,464,302.00 in new funding. Sources indicate as part of senior management Chief Executive Officer, Brian Finrow played a key role in securing the recent investment and it will aid in aggressively expanding the company, as well as broaden and accelerate product development.

About Lumen Bioscience
Lumen unlocks the full potential of biologic drugs, whose promise has been held back by the lack of scalable technology. Our goal is to transform the way such drugs are developed, what they cost, and who has access to them. Our patented technology allows us to develop biologic drugs faster and with lower cost and risk than traditional methods. Many highly prevalent diseases have proven impossible to treat with traditional drug-making tools, despite decades of research, so they’ve been essentially abandoned by drug makers. Lumens unique technology is ideally suited to finally address these indications.

To learn more about Lumen Bioscience, visit http://www.lumenbioscience.com/

Contact:
Brian Finrow, Chief Executive Officer
206-899-1904
https://www.linkedin.com/in/finrow/

SOURCE: http://www.intelligence360.io
Copyright (c) 2022 SI360 Inc. All rights reserved